The Robotic Surgery and Minimally Invasive Urologic Oncology (RSMIUO) Fellowship at the University of Florida (UF) is a comprehensive, yet flexible, multidisciplinary training opportunity that provides fellows the chance to learn from fellowship-trained leaders in both the Endourological Society and Society of Urologic Oncology who have mastery in laparoscopic and robotic surgery as well as focal therapy. In addition, our team has a strong history of excellence with both investigator-initiated, industry-sponsored, and co-operative group clinical trials within the NCI-designated UF Health Cancer Center (UFHCC).
During the year, trainees will spend time on clinical rotations and will be directly involved in the management of patients with various urologic malignancies and will be exposed to a broad spectrum of minimally invasive surgical procedures including:
- Prostate
- High volume prostate surgery center with dedicated teaching team (>150 prostatectomy/year)
- Robotic prostatectomy with various approaches: anterior, posterior, Retzius-sparing and Hood technique
- Robotic salvage prostatectomy experience
- da Vinci multiport and SP platform
- Fusion and transperineal biopsy experience (opportunity to learn micro-ultrasound)
- Mentors: Drs. Benidir, Joseph, Su
- Focal Therapy
- High intensity frequency ultrasound (HIFU)
- Irreversible electroporation (IRE)
- Transurethral ultrasound ablation (TULSA)
- Cryoablation
- Mentor: Dr. Benidir
- Kidney
- Robotic and laparoscopic radical nephrectomy, nephroureterectomy, partial nephrectomy, and caval thrombectomy (>300 renal cases/year)
- Transperitoneal and retroperitoneal approaches (traditional, SARA)
- da Vinci multiport and SP platform
- Mentors: Drs. Benidir, Crispen, Joseph, O’Malley, Su
- Bladder
- Advanced understanding of urothelial carcinoma
- Clinical trials: learn the ins and outs of running clinical trials effectively and receive mentorship in designing investigator-initiated trials
- Robotic radical cystectomy, robotic partial cystectomy (>50 radical cystectomy alone/year)
- Intracorporeal (and extracorporeal) urinary diversions: conduit, Indiana pouch, neobladder
- da Vinci multiport and SP platform
- Transurethral resection of bladder tumors (Blue light)
- Nephron sparing endoscopic approaches (Thulium)
- Mentors: Drs. Benidir, Crispen, O’Malley
- Testis
- Robotic retroperitoneal lymph node dissection
- Transperitoneal, da Vinci multiport
- Mentor: Dr. O’Malley
Application to the Program
If you are interested in applying for the Fellowship Program, please visit the Endourological Society’s website Endourology Society UF Fellowship Application to download and complete the application. After completion, you should email a pdf of your application and your curriculum vitae, to: Jennifer.Thompson@urology.ufl.edu
Program Faculty
Tarik Benidir MD
- Physical Address:
-
1600 SW ARCHER RD
GAINESVILLE FL 32610
My name is Tarik Benidir, MD, and I am a clinical assistant professor at the University of Florida Department of Urology. I received my medical degree from Queens University School of Medicine in Kingston, Ontario, followed by a residency in urology at the University of Toronto and a urologic oncology fellowship at the Cleveland Clinic in Ohio.
As a urologist that specializes in urologic cancer, I provide surgical management to patients with localized or locally advanced prostate cancer. I offer treatment through robotic prostatectomy for the whole gland as well as prostate focal therapy using various modalities. Furthermore, I am trained to utilize robotic cystectomy with intracorporal diversion for bladder cancer management and other robotic procedures for kidney and ureteral cancers.
My research focuses on the optimization of patient selection for prostate focal therapy and the use of genomics, advanced imaging and artificial intelligence to better treat prostate cancer patients.
In addition to my clinical practice, I enjoy educating and mentoring the next generation of urologists.
- Surgical Oncology
- Urology
- Bladder Cancer
- Focal Therapy for Prostate Cancer
- Focal Therapy: High-Intensity Focused Ultrasound for Prostate Cancer (HIFU)
- Kidney Cancer
- Laparoscopic Radical Nephrectomy
- Laparoscopic and Robotic Nephroureterectomy
- Laparoscopic and Robotic Partial Nephrectomy
- Prostate Biopsy
- Prostate Cancer
- Transperineal Biopsy for Prostate Cancer
- UF Health robotic prostatectomy
- Upper Tract Urothelial Cancer
- Urologic Cancer
- 2025 Urology
- 2024 Computerized medical imaging and graphics : the official journal of the Computerized Medical Imaging Society
- 2024 Urologic oncology
- 2023 The Journal of urology
- 2023 Archives of pathology & laboratory medicine
- 2023 The British journal of radiology
- 2023 The Urologic clinics of North America
- 2023 Urology
- 2023 Urology practice
- 2023 Urology practice
- 2023 The journal of pathology. Clinical research
- 2023 Urology
- 2022 The Journal of urology
- 2022 The Journal of urology
- 2022 The Journal of urology
- 2022 Urologic oncology
- 2022 International urology and nephrology
- 2022 Urology
- 2022 Urology
- 2022 European urology focus
- 2021 Cancer medicine
- 2021 F&S reports
- 2018 Urologic oncology
- 2014 Canadian Urological Association journal = Journal de l'Association des urologues du Canada
- 2014 Canadian Urological Association journal = Journal de l'Association des urologues du Canada
- 2013 Canadian Urological Association journal = Journal de l'Association des urologues du Canada
- 2013 Molecular and cellular endocrinology
-
Nov 2024
ACTIVE
Salvage Focal Therapy via High Intensity Focused Ultrasound (HIFU) in Radiorecurrent Localized Prostate Cancer (FocalHIFU) (NCT06402357)EDAP TECHNOMED · Principal Investigator
-
2021-2023
Fellowship, Urologic OncologyCleveland Clinic
-
2016-2021
Residency, UrologyUniversity of Toronto
-
2012-2016
Medical SchoolQueens University School of Medicine
Paul L Crispen M.D.
- Mailing Address:
-
PO Box 100247
GAINESVILLE FL 32610
- Physical Address:
-
1600 SW ARCHER RD
GAINESVILLE FL 32610
As a urologic oncologist, I specialize in the surgical treatment of urothelial carcinoma of the bladder, kidney and ureters. My training as a Urologic Oncologist began at Temple University School Medicine where I received my medical degree and completed a Urology residency. Following completion of residency I received fellowship training in Urologic Oncology at the Mayo Clinic.
My clinical interests focus on the surgical management of bladder cancer, including radical cystectomy and minimally invasive techniques such as laparoscopic robotic cystectomy. While my practice focuses on the surgical management of urologic malignancies I place great emphasis on multidisciplinary cancer care involving medical and radiation oncologists.
My research interest is primarily related to improving the evaluation and treatment of patients presenting with genitourinary malignancies. To date, most of my research effort has focused on the management of bladder and kidney cancer. Additionally, I have a strong interest in involving appropriately selected patients in clinical trials which are designed to evaluate new treatment regimens and hopefully improve the care of patients at the University of Florida and beyond.
-
Golden Gator Award2018 · UFHealth Cancer Center
-
Gold Humanism Award2018 · University of Florida School of Medicine
-
Examplary Teacher Award2018 · University of Florida College of Medicine
-
UF Honored Care Giver2017 · UFHealth
-
Resident Teaching Award2017 · Department of Urology, University of Florida
-
Exemplary Teacher Award2017 · University of Florida College of Medicine
-
Physician Recognition Award2016 · UFHealth
-
UF Health Cancer Center MVP Award2015 · UF Health Cancer Center
-
Shands Patient Service Recognition Award2014 · UF Health Shands
-
ASCO Foundation Merit Award, GU ASCO2009 · ASCO Foundation
-
Outstanding Poster Presentation2005 · Society of Urologic Oncology
-
UrologyAmerican Board of Urology
- Cancer
- Urology
- Bladder Biopsy
- Bladder Cancer
- Cystoscopy
- Cytology Exam of Urine
- Kidney Cancer
- Penile Cancer
- Renal Cell Carcinoma
- Renal Pelvis or Ureter Cancer
- Robotic and Laparoscopic Urologic Surgery
- Testicular Cancer
- Upper Tract Urothelial Cancer
- Urologic Cancer
- 2025 The Lancet. Oncology
- 2024 Frontiers in endocrinology
- 2024 The Journal of urology
- 2024 Urologic oncology
- 2023 The Journal of urology
- 2023 Journal of visualized experiments : JoVE
- 2023 Methods in molecular biology (Clifton, N.J.)
- 2023 European urology focus
- 2023 Advanced biology
- 2022 Urology case reports
- 2022 European urology
- 2022 Journal of kidney cancer and VHL
- 2022 Journal of immunology (Baltimore, Md. : 1950)
- 2022 Cancers
- 2021 The Lancet. Oncology
- 2021 Cancer research
- 2021 European journal of pain (London, England)
- 2021 Anesthesiology
- 2021 Abdominal radiology (New York)
- 2021 Abdominal radiology (New York)
- 2020 Cancer immunology, immunotherapy : CII
- 2019 Urology
- 2018 Bladder cancer (Amsterdam, Netherlands)
- 2017 The Urologic clinics of North America
- 2017 Journal of kidney cancer and VHL
- 2016 Case reports in oncological medicine
- 2016 Urology practice
- 2015 Urology
- 2015 Case reports in oncological medicine
- 2015 The Journal of urology
- 2015 Journal of kidney cancer and VHL
- 2015 Clinical cancer research : an official journal of the American Association for Cancer Research
- 2015 The Journal of urology
- 2014 Urologic Oncology
- 2014 Current opinion in urology
- 2013 Journal of endourology
- 2013 Nature reviews. Urology
- 2013 BJU international
- 2013 Urology
- 2013 Canadian Urological Association journal = Journal de l'Association des urologues du Canada
- 2012 Current urology reports
- 2012 Pathology
- 2012 The Canadian journal of urology
- 2012 Cancer
- 2012 The Journal of urology
- 2012 The Journal of urology
- 2011 European urology
- 2011 The Journal of urology
- 2011 Urology
- 2011 Journal of endourology
- 2011 BJU international
- 2011 Journal of endourology
- 2010 Journal of the American College of Surgeons
- 2010 The Journal of urology
- 2010 The Journal of urology
- 2010 The Journal of urology
- 2010 Diagnostic pathology
- 2010 Cancer
- 2010 The Urologic clinics of North America
- 2010 Urology
- 2009 Kidney Cancer Journal
- 2009 The Journal of urology
- 2009 European urology
- 2009 Clinical cancer research : an official journal of the American Association for Cancer Research
- 2009 European urology
- 2009 Cancer
- 2009 Urology
- 2009 Urology
- 2009 The Journal of urology
- 2008 Cancer
- 2008 Cancer
- 2008 Nature clinical practice. Urology
- 2008 The Journal of urology
- 2008 Urology
- 2008 Journal of endourology
- 2008 Clinical cancer research : an official journal of the American Association for Cancer Research
- 2008 Clinical cancer research : an official journal of the American Association for Cancer Research
- 2008 Cancer
- 2008 Advances in urology
- 2008 Urology
- 2008 The Prostate
- 2008 European urology
- 2008 Urology
- 2008 Cell death and differentiation
- 2008 Urologic oncology
- 2008 The Journal of urology
- 2008 BJU international
- 2007
- 2007 The Journal of trauma
- 2007 The Journal of urology
- 2007 The Prostate
- 2007 The Journal of urology
- 2007 BJU international
- 2006 The Journal of urology
- 2006 Carcinogenesis
- 2005 BJU international
- 2005 Oncogene
-
Jul 2025
ACTIVE
Florida Partnership for Adding Social Context to Address Cancer Survivorship Outcomes (ASCENT)FL DEPT OF HLTH · Co-Investigator
-
Apr 2025
ACTIVE
A Phase 1 Dose Escalation Study of STM-416p Administered Intraoperatively to Patients Undergoing Radical ProstatectomySURGE THERAPEUTICS · Principal Investigator
-
Jan 2025
ACTIVE
PD-INHIBITOR (NIVOLUMAB) AND IPILIMUMAB FOLLOWED BY NIVOLUMAB VS. VEGF TKI CABOZANTINIB WITH NIVOLUMAB: A PHASE III TRIAL IN METASTATIC UNTREATED RENAL CELL CANCER [PDIGREE]NRG ONCOLOGY FOU · Principal Investigator
-
Jan 2025
ACTIVE
A Phase 3, Randomized, Open-label Study to Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Gemcitabine and Cisplatin in Cisplatin-eligible Participants with Muscle-invasive Bladder Cancer (KEYNOTE-B15 / EV-304)Merck Sharp & Dohme · Principal Investigator
-
Nov 2024
ACTIVE
Phase III Randomized Trial of DFP-10917 vs. Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine, Venetoclax Combination Regimens) or Intensive Reinduction (High and Intermediate Dose Cytarabine Regimens) for Acute Myelogenous Leukemia Patients in Second, Third, or Fourth SalvageDELTA-FLY PHARMA · Principal Investigator
-
Nov 2024
ACTIVE
Salvage Focal Therapy via High Intensity Focused Ultrasound (HIFU) in Radiorecurrent Localized Prostate Cancer (FocalHIFU) (NCT06402357)EDAP TECHNOMED · Faculty
-
Nov 2024
ACTIVE
Randomized Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients up to 65 Years of AgeDANA FARBER CANCER INST · Principal Investigator
-
Oct 2024
ACTIVE
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid TumorsEXELIXIS · Principal Investigator
-
Sep 2024
ACTIVE
LLS funding for Improving risk assessment of AML with a precision genomic strategy to assess mutation clearanceBLOOD CANCER UNITED · Principal Investigator
-
Jul 2024
ACTIVE
Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)NRG ONCOLOGY FOU · Principal Investigator
-
Jul 2024
ACTIVE
Enhancing Connection and Communication with Community-Based Oncology Practices to Improve Cancer Clinical Trial Recruitment: The ECCO StudyBLOOD CANCER UNITED · Co-Investigator
-
Mar 2024
ACTIVE
Adstiladrin Early Utilization and Outcomes in the Real World Setting in the United StatesFERRING PHARMACEUTICALS · Principal Investigator
-
Aug 2023
–
Aug 2024
ASCO Screening and Enrollment Qualitative StudyAMER SOC FOR CLINICAL ONCOLOGY · Principal Investigator
-
Jun 2023
ACTIVE
UF Health Cancer Center Support GrantNATL INST OF HLTH NCI · Other
-
Mar 2022
–
Oct 2023
A Phase 2, Open-Label, Multi-Center, Randomized Study of TAR-200 in Combination with Cetrelimab and Cetrelimab Alone in Participants with Muscle-Invasive Urothelial Carcinoma of the Bladder who are Scheduled for Radical Cystectomy and are Ineligible for or Refusing Platinum-Based Neoadjuvant ChemotherapyJANSSEN RESEARCH AND DEVELOPMENT · Principal Investigator
-
Mar 2022
ACTIVE
A Phase 2, Open-Label, Multi-Center, Randomized Study of TAR-200 in Combination with Cetrelimab and Cetrelimab Alone in Participants with Muscle-Invasive Urothelial Carcinoma of the Bladder who are Scheduled for Radical Cystectomy and are Ineligible for or Refusing Platinum-Based Neoadjuvant ChemotherapyJANSSEN RESEARCH AND DEVELOPMENT · Principal Investigator
-
Feb 2022
ACTIVE
Phase 1/2, open-label, multicenter study to evaluate a dosing regimen with two step-up priming doses and longer dosing intervals of Elranatamab (PF-06863135) monotherapy in participants with relapsed/refractory multiple myelomaPFIZER INC · Principal Investigator
-
Nov 2021
ACTIVE
Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)NRG ONCOLOGY FOU · Principal Investigator
-
Apr 2021
–
Jan 2022
Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer (Study SWOG/NRG S1806)NRG ONCOLOGY FOU · Principal Investigator
-
Aug 2020
ACTIVE
A Randomized Phase II Trial of Salvage Radiotherapy with Standard vs Enhanced Androgen Deprivation Therapy (with Enzalutamide) in Patients with Post-Prostatectomy PSA Recurrences with Aggressive Disease FeaturesRADIATION THERAPY ONCOLOGY GROUP FOU · Principal Investigator
-
Jul 2020
ACTIVE
Phase III Study of Daratumumab/rHuPH20 (NSC- 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)NRG ONCOLOGY FOU · Principal Investigator
-
Mar 2020
–
Apr 2020
NCTN High Performing Site Initiative (HPSI)PPD DEVELOPMENT · Principal Investigator
-
Nov 2019
–
Jan 2020
NCTN High Performing Site Initiative (HPSI)PPD DEVELOPMENT · Principal Investigator
-
May 2019
ACTIVE
PD-INHIBITOR (NIVOLUMAB) AND IPILIMUMAB FOLLOWED BY NIVOLUMAB VS. VEGF TKI CABOZANTINIB WITH NIVOLUMAB: A PHASE III TRIAL IN METASTATIC UNTREATED RENAL CELL CANCER [PDIGREE]NRG ONCOLOGY FOU · Principal Investigator
-
May 2019
ACTIVE
A Phase III Randomized, Double-Blind Study of Maintenance Therapy with CC-5013 (NSC # 703813, IND # 70116) or Placebo Following Autologous Stem Cell Transplantation for Multiple MyelomaNRG ONCOLOGY FOU · Principal Investigator
-
Mar 2019
–
Feb 2025
Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer (Study SWOG/NRG 1806)NRG ONCOLOGY FOU · Principal Investigator
-
Mar 2019
ACTIVE
Phase III Study of Daratumumab/rHuPH20 (NSC- 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC StuNRG ONCOLOGY FOU · Principal Investigator
-
Mar 2019
ACTIVE
PHASE III RANDOMIZED ADJUVANT STUDY OF MK-3475 (PEMBROLIZUMAB) IN MUSCLE INVASIVE AND LOCALLY ADVANCED UROTHELIAL CARCINOMA (AMBASSADOR) VERSUS OBSERVATIONNRG ONCOLOGY FOU · Principal Investigator
-
Mar 2019
ACTIVE
PHASE III RANDOMIZED ADJUVANT STUDY OF MK-3475 (PEMBROLIZUMAB) IN MUSCLE INVASIVE AND LOCALLY ADVANCED UROTHELIAL CARCINOMA (AMBASSADOR) VERSUS OBSERVATIONNRG ONCOLOGY FOU · Principal Investigator
-
Mar 2019
ACTIVE
PHASE II TRIAL OF INTRAVESICAL GEMCITABINE AND MK-3475 (PEMBROLIZUMAB) IN THE TREATMENT OF PATIENTS WITH BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCERNRG ONCOLOGY FOU · Principal Investigator
-
Mar 2019
ACTIVE
NRG Affiliate Master-FederalNRG ONCOLOGY FOU · Principal Investigator
-
Sep 2018
–
Sep 2023
Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder CancerSWOG CLINICAL TRIALS INITIATIVE · Principal Investigator
-
Jul 2018
ACTIVE
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study Evaluating the Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and G-GSF as Compared to Placebo and G-CSF for thE MobilizatioN of HematopoiEtic Stem Cells for Autologous TransplantatIon in SubjectS With Multiple Myeloma – The GENESIS StudyBIOLINE RX · Principal Investigator
-
May 2018
–
Mar 2021
Dissecting the Mechanisms of Tumor-Induced Tolerance and Immune SuppressionFL DEPT OF HLTH BIOMED RES PGM/J&E KING · Faculty
-
Mar 2018
–
Feb 2019
NRG ONCOLOGY NETWORK GROUP OPERATIONS CENTERNRG ONCOLOGY FOU · Principal Investigator
-
Jan 2018
ACTIVE
A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG-Na?ve High-Grade Non-Muscle Invasive Bladder CancerNRG ONCOLOGY FOU · Principal Investigator
-
Sep 2017
–
May 2024
A Phase III, Open Label Study to Evaluate the Safety and Efficay of INSTILADRIN (rAd-IFN/Syn3) Administered Intravesically to Patients with High Grad, BCG Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)FKD THERAPIES · Principal Investigator
-
Jun 2017
–
Oct 2023
A PHASE III, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) AS ADJUVANT THERAPY IN PATIENTS WITH RENAL CELL CARCINOMA AT HIGH RISK OF DEVELOPING METASTASIS FOLLOWING NEPHRECTOMYSYNEOS HEALTH · Principal Investigator
-
Feb 2017
–
Feb 2022
Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder CancerNRG ONCOLOGY FOU · Principal Investigator
-
Aug 2016
–
Dec 2022
A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab versus Placebo in Subjects with High Risk Invasive Urothelial CarcinomaBRISTOL MYERS SQUIBB CO · Principal Investigator
-
May 2016
–
Aug 2022
A RANDOMIZED DOUBLE BLINDED PHASE II STUDY OF MAINTENANCE PEMBROLIZUMAB VERSUS PLACEBO AFTER FIRST LINE CHEMOTHERAPY..HOOSIER CANCER RESEARCH NETWORK · Principal Investigator
-
Jul 2015
–
Jul 2020
AN OPEN LABEL, SINGLE ARM PHASE II MULTICENTER STUDY OF THE SAFETY AND EFFICACY OF CG0070 ONCOLYTIC VECTOR REGIMEN INCG ONCOLOGY · Principal Investigator
-
Jan 2015
–
Sep 2021
A PHASE III RANDOMIZED CLINICAL TRIAL OF PEMBROLIZUMAB (MK-3475) VERSUS PACLITAXEL, DOCETAXEL OR VINFLUNINE….Merck Sharp & Dohme · Principal Investigator
-
Published
December 2022
Materials and Methods for the Diagnosis and Treatment of Cancer#US-2023-0341408-A1
-
2009
Fellowship – Urologic OncologyMayo Clinic
-
2007
Residency – UrologyTemple University Hospital
-
2001
M.D.Temple University School of Medicine
John Michael DiBianco M.D.
- Physical Address:
-
1600 SW Ar
GAINESVILLE FL 32611
My name is John Michael DiBianco, MD, and I joined the department of urology in 2022. I received my bachelor’s degree in psychology from Trinity College in Hartford, Connecticut and medical degree from Ross University School of Medicine. I completed a general surgery internship and urologic surgery residency at George Washington University School of Medicine & Health Sciences in Washington, D.C. Afterward, I completed a fellowship in endourology at the University of Michigan.
I am now an assistant professor in the department of urology, and my clinical interests include general surgical urology, minimally invasive surgery and specifically the management of kidney stone disease and symptomatic prostate enlargement. My research focus includes quality improvement (QI), the goal of which is to improve the delivery, experience and outcomes of care. I aim to ensure that the choice of treatment is medically appropriate while aligning with the goals of the patient.
In my free time, I enjoy exercising to stay both physically and mentally fit. Additionally, I enjoy movies and experiencing how new movies compare to the classics.
- Urology
- Benign Prostate Hyperplasia (enlarged prostate)
- Kidney Stones
- Laparoscopic Renal Cyst Ablation
- Laparoscopic Robotic Pyeloplasty
- Lithotripsy
- Percutaneous kidney procedures
- Robotic and Laparoscopic Urologic Surgery
- Transperineal Biopsy for Prostate Cancer
- Ureteroscopy
- 2025 World journal of urology
- 2025 Journal of Urology
- 2024 Urology practice
- 2024 Computerized medical imaging and graphics : the official journal of the Computerized Medical Imaging Society
- 2024 Current urology reports
- 2024 Journal of endourology
- 2024 Frontiers in surgery
- 2024 Kidney360
- 2024 Journal of Urology
- 2024 Biomedical Signal Processing and Control
- 2024 Urology Video Journal
- 2023 Journal of Endourology
- 2023 Urology Practice
- 2023 European urology focus
- 2023 The Journal of urology
- 2023 Urology
- 2023 Urology
- 2022 Anaesthesia
- 2022 Urology
- 2022 Urology Video Journal
- 2022 World Journal of Urology
- 2021 Current Urology Reports
- 2021 The Journal of urology
- 2021 The British journal of surgery
- 2021 Journal of Endourology
- 2021 Anaesthesia
- 2021 Urology
- 2020 Translational andrology and urology
- 2019 Urology
- 2019 Journal of endourology case reports
- 2019 Urology
- 2019 Annals of translational medicine
- 2018 Urology annals
- 2018 Annals of translational medicine
- 2017 The Journal of urology
- 2017 Prostate cancer and prostatic diseases
- 2017 Urology case reports
- 2017 Urology practice
- 2016 Urology practice
- 2016 Journal of wound, ostomy, and continence nursing : official publication of The Wound, Ostomy and Continence Nurses Society
- 2016 Journal of wound, ostomy, and continence nursing : official publication of The Wound, Ostomy and Continence Nurses Society
- 2016 The West Virginia medical journal
- 2016 Clinical genitourinary cancer
- 2015 Cancer
- 2015 SpringerPlus
- 2015 Current opinion in urology
- 2015 Reviews in urology
- 2014 BMC surgery
- 2014 European urology
- 2014 Avicenna journal of medicine
-
May 2024
–
Nov 2025
Stent Omission after Ureteroscopy and Lithotripsy in the Michigan Urological Surgery Improvement Collaborative (SOUL MUSIC)UNIV OF MICHIGAN · Principal Investigator
-
2020-2022
Fellowship, EndourologyUniversity of Michigan
-
2016-2020
Residency, Urologic SurgeryGeorge Washington University
-
2015-2016
Internship, General SurgeryGeorge Washington University
-
2010-2014
Medical SchoolRoss University
Padraic O'Malley MSc, MD, FRCSC
- Mailing Address:
-
PO Box 100247
GAINESVILLE FL 32610
- Physical Address:
-
PO Box 100247
GAINESVILLE FL 32610
My name is Padraic O’Malley, MSc, MD, FRCSC, and I am a clinical assistant professor in the University of Florida Department of Urology and chief of urologic oncology. Following medical school at Saba University School of Medicine, I completed my urology residency at the University of Toronto in Toronto, Canada, where I was awarded the Undergraduate Teaching Award. I completed my urologic oncology fellowship at Weill-Cornell Medical College in New York, New York, where I was awarded the Ferdinand C. Valentine Fellowship Award. I joined UF Health in 2018 and have since been awarded a UF College of Medicine Exemplary Teacher award as well as the Department of Urology Rising Star Award.
Currently, I am a board member of the Florida Urological Society and Southeastern section of the American Urological Association. I am also a member of the American Urological Association, the Canadian Urological Association, the Endourological Society and the Society of Urologic Oncology, in addition to being an international member of the European Association of Urology. Along with seeing patients and teaching, I have contributed as an author to a number of urology-based publications, chapters and abstracts.
My clinical interests revolve around urologic oncology, multidisciplinary care and robotic surgical techniques. I perform complex robotic surgery with a special interest in bladder and kidney cancer. This includes treating IVC thrombus, performing robotic and open tumor thrombectomies, and robotic and open retroperitoneal lymph node dissection. I serve as a sub-investigator on a number of clinical trials for bladder, kidney and prostate cancer. My research interests examine the tumor microenvironment in bladder and kidney cancer, the use of novel nanoparticle and artificial intelligence-powered analysis of exosome-based, multi-fluid multi-omics in bladder cancer, and the use of surgery in advanced kidney cancer.
During my free time, I enjoy spending time with my wife and children, traveling, playing and watching sports (rugby, in particular), and cooking with my smoker.
-
UrologyThe American Board of Urology
- Cancer
- Urology
- Adrenocortical Carcinoma
- Bladder Cancer
- Kidney Cancer
- Kidney Removal
- Laparoendoscopic Single Site (LESS) Surgery
- Laparoscopic Radical Nephrectomy
- Laparoscopic and Robotic Nephroureterectomy
- Laparoscopic and Robotic Partial Nephrectomy
- Penile Cancer
- Prostate Cancer
- Renal Cell Carcinoma
- Renal Vein Thrombosis
- Robotic Surgery
- Robotic and Laparoscopic Urologic Surgery
- Testicular Cancer
- UF Health robotic prostatectomy
- Upper Tract Urothelial Cancer
- Urologic Cancer
- Minimally invasive urological surgical therapies
- Urologic Oncology
- 2024 Research and reports in urology
- 2024 Urologic oncology
- 2023 The Journal of urology
- 2023 Journal of visualized experiments : JoVE
- 2023 Advanced biology
- 2023 European urology
- 2022 Urologic oncology
- 2022 Journal of kidney cancer and VHL
- 2022 The Journal of Immunology
- 2022 Pharmaceutics
- 2022 Cancers
- 2021 Cancer research
- 2021 Abdominal radiology (New York)
- 2021 Journal of endourology
- 2021 The Journal of urology
- 2021 Abdominal radiology (New York)
- 2020 Urology practice
- 2018 Urology
- 2018 The Canadian journal of urology
- 2017 BJU international
- 2017 The Journal of urology
- 2017 Journal of endourology
- 2017 The Journal of urology
- 2017 Clinical genitourinary cancer
- 2017 World journal of urology
- 2017 The Journal of urology
- 2017 Clinical genitourinary cancer
- 2017 World journal of urology
- 2017 Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
- 2016 European urology
- 2016 BJU international
- 2016 The Annals of thoracic surgery
- 2016 Journal of surgical oncology
- 2016 The Journal of urology
- 2015 Urology
- 2015 European urology
- 2014 Canadian Urological Association journal = Journal de l'Association des urologues du Canada
- 2010 European urology
- 2005 The Biochemical journal
-
Sep 2025
ACTIVE
A Phase 3, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-104, a Novel Formulation of UGN-101, for the Treatment of Patients With Low-grade Upper Tract Urothelial Cancer (LG-UTUC)UROGEN PHARMA LTD · Principal Investigator
-
Jun 2025
ACTIVE
A Phase 2, Multi-Arm, Multi-Cohort, Open-Label Study to Evaluate the Safety and Efficacy of Cretostimogene Grenadenorepvec in Participants with High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)CG ONCOLOGY · Principal Investigator
-
Jun 2025
ACTIVE
GAIN-BCG: Gemcitabine Alternating with INtravesical BCG randomized against BCG alone for patients with recurrent high grade Non-Muscle Invasive Bladder CancerNRG ONCOLOGY FOU · Principal Investigator
-
May 2025
ACTIVE
A 3-arm randomized controlled trial evaluating the role of 29MHz micro-ultrasound in guiding prostate biopsy in men with clinical suspicion of prostate cancerEXACT IMAGING · Principal Investigator
-
Nov 2024
ACTIVE
Salvage Focal Therapy via High Intensity Focused Ultrasound (HIFU) in Radiorecurrent Localized Prostate Cancer (FocalHIFU) (NCT06402357)EDAP TECHNOMED · Faculty
-
Aug 2024
ACTIVE
a multi- center registry under a protocol entitled uTRACT Registry Jelmyto? (mitomycin) for pyelocalyceal solution (the Drug)UROGEN LTD · Principal Investigator
-
May 2024
ACTIVE
A Phase 1/2a Study of STM-416 Administered Intraoperatively to Patients Undergoing Transurethral Resection of Bladder Tumor (TURBT) for Recurrent High-Grade Papillary Bladder CancerSURGE THERAPEUTICS · Principal Investigator
-
Jan 2023
ACTIVE
A Randomized Phase III Trial of Intravesical BCG veRsus Intravesical Docetaxel and GEmcitabine Treatment in BCG Na?ve High Grade Non-Muscle Invasive Bladder Cancer (BRIDGE)NRG ONCOLOGY FOU · Principal Investigator
-
Sep 2022
ACTIVE
UF HEALTH CANCER CENTER PILOT PROJECTS GRANTS FUNDED THROUGHTHE FLORIDA CONSORTIUM OF NATIONAL CANCER INSTITUTE CENTERUF HEALTH SHANDS HOSPITAL · Project Manager
-
Apr 2022
–
Jan 2024
Pivotal Study of the NanoKnife System for Ablation of Prostate Tissue in an Intermediate-Risk Patient PopulationANGIODYNAMICS · Principal Investigator
-
Apr 2022
–
May 2025
Pivotal Study of the NanoKnife System for Ablation of Prostate Tissue in an Intermediate-Risk Patient PopulationANGIODYNAMICS · Principal Investigator
-
Apr 2022
–
May 2025
A 3-arm randomized controlled trial evaluating the role of 29MHz micro-ultrasound in guiding prostate biopsy in men with clinical suspicion of prostate cancerEXACT IMAGING · Principal Investigator
-
Nov 2020
ACTIVE
Phase III Trial of Immunotherapy-Based Combination Therapy with or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (PROBE trial)NRG ONCOLOGY FOU · Principal Investigator
-
2014-2016
Fellowship, Urological OncologyWeill Cornell Medical College and New York Presbyterian Hospital
-
2009-2014
ResidencyUniversity of Toronto
-
2005-2009
Medical SchoolSaba University School of Medicine
Li-Ming Su M.D.
- Mailing Address:
-
PO Box 100247
GAINESVILLE FL 32610
- Physical Address:
-
1600 SW ARCHER RD
GAINESVILLE FL 32610
My name is Li-Ming Su, MD, and I am the Pete and Carolyn Newsome Professor of Urologic Oncology and Chair of the University of Florida Department of Urology. I completed my residency in urology at the New York Presbyterian Hospital-Weill Cornell Medical College and an advanced fellowship in robotics and laparoscopic surgery at The Johns Hopkins Hospital. Prior to joining UF, I served eight years on faculty at the James Buchanan Brady Urological Institute at Johns Hopkins. As a proud Gainesville native, I am glad to be serving the community I grew up in and am especially proud to lead the No. 1 academic urology program in the state of Florida.
My clinical interests include minimally invasive laparoscopic and robotic surgery for prostate cancer, kidney cancer, adrenal tumors and urothelial cancer of the kidney. My research focus is on exploring advanced imaging as applied to urologic oncologic surgery.
As a physician, my goal is to provide patients with outstanding, compassionate care tailored to their unique circumstance and urologic condition.
Outside of medicine, I enjoy saltwater fishing, playing tennis, raising koi fish and spending time with my wife, son, and two dogs.
-
Secretary General2021-Current · Endourological Society
-
Certificate of Recognition for education and teaching as well as outstanding professional accomplishments2021 · American Urological Association
-
Diploma of Fellowship FRCS(Glasg)2020-Current · Royal College of Physicians and Surgeons of Glasgow
-
American Board of Urology Oral Examination Committee2020-Current · American Board of Urology
-
American Board of Urology Written Emanation Committee2012-2015 · American Board of Urology
-
America’s Top Doctors for Cancer2010-2021 · Castle Connolly Medical Ltd
-
Distinguished Customer Service Award2009 · UF Health
-
First Prize, Audio-Visual Award: Nerve-sparing during laparoscopic radical prostatectomy: adhering to the high standard of open surgery2004 · American Urological Association Meeting
-
First Prize, Ambrose-Reed Socioeconomic Essay Contest: Making ends meet: a cost comparison of laparoscopic and open radical retropubic prostatectomy2004 · American Urological Association Meeting
-
UrologyAmerican Board of Urology
- Urology
- Adrenal Gland Removal
- Adrenocortical Carcinoma
- Cushing Syndrome Due to Adrenal Tumor
- Kidney Cancer
- Laparoscopic Radical Nephrectomy
- Laparoscopic Renal Cyst Ablation
- Laparoscopic Robotic Pyeloplasty
- Laparoscopic and Robotic Nephroureterectomy
- Laparoscopic and Robotic Partial Nephrectomy
- Laparoscopy and Robotic Adrenalectomy
- Pheochromocytoma
- Prostate Cancer
- Renal Cell Carcinoma
- Renal Pelvis or Ureter Cancer
- Robotic Surgery
- Robotic and Laparoscopic Urologic Surgery
- UF Health robotic prostatectomy
- Upper Tract Urothelial Cancer
- Urologic Cancer
Dr. Su’s clinical interests are in minimally invasive surgical therapies for kidney cancer and robotic prostatectomy for prostate cancer.
His research focuses on exploring advanced imaging for prostate and kidney cancer, robotic simulation and  and trialing new minimally invasive biomedical technology.
Specialties: Robotic and laparoscopic surgery for prostate, urothelial and kidney cancer, adrenal tumors, and kidney obstruction (pyeloplasty)
- 2025 Cancer Prevention Research
- 2024 Urology case reports
- 2024 Computerized medical imaging and graphics : the official journal of the Computerized Medical Imaging Society
- 2024 Urologic oncology
- 2023 Journal of visualized experiments : JoVE
- 2023 Cancer control : journal of the Moffitt Cancer Center
- 2021 Abdominal radiology (New York)
- 2021 Journal of endourology
- 2021 Abdominal radiology (New York)
- 2020 Journal of endourology case reports
- 2020 The Journal of urology
- 2019 Urology
- 2018 Bladder cancer (Amsterdam, Netherlands)
- 2017 Journal of kidney cancer and VHL
- 2016 The Journal of urology
- 2016 Journal of endourology
- 2015 Current urology reports
- 2015 Asian journal of urology
- 2015 Journal of kidney cancer and VHL
- 2015 Journal of robotic surgery
- 2014 Current opinion in urology
- 2014 Urology case reports
- 2013 IEEE transactions on visualization and computer graphics
- 2013 Clinical cancer research : an official journal of the American Association for Cancer Research
- 2013 BJU international
- 2012 BJU international
- 2011 Cancer research
- 2011 JSLS : Journal of the Society of Laparoendoscopic Surgeons
- 2010 Current opinion in urology
- 2009 Urology
- 2009 The Urologic clinics of North America
- 2009 Therapeutic advances in urology
- 2008 The Journal of urology
- 2007 Urology
- 2005 Urology
- 2005 Current urology reports
- 2002 Urology
- 2002 Urology
- 1998 Urology
- 1997 Human reproduction (Oxford, England)
- 1995 The Journal of urology
-
Sep 2025
ACTIVE
Urology CTOAUNIV OF FLORIDA · Principal Investigator
-
Sep 2018
–
Aug 2023
2/3 Florida-California Cancer Research, Education & Engagement (CaRE2) Health Equity CenterNATL INST OF HLTH NCI · Other
-
2001
Fellowship – Minimally Invasive SurgeryBrady Urological Institute – Johns Hopkins Hospital
-
2000
Residency – UrologyNew York Presbyterian Hospita l- Cornell
-
1996
Residency – SurgeryNew York Presbyterian Hospital – Cornell
-
1995
Internship – SurgeryNew York Presbyterian Hospital – Cornell
-
1994
Medical DegreeWeill-Cornell University Medical College

